Managing Director and Senior Biotech Analyst, Charles C. Duncan, PhD, kicked off Cantor’s “Brain Week 2022” by hosting Harmony Biosciences for a virtual fireside chat.

• The discussion with senior management of Harmony focused on the commercial potential for lead product, WAKIX, in narcolepsy as well as TAM expansion opportunities in the pipeline.

• Charles believes WAKIX can become a >$1B/year franchise in narcolepsy alone due, in his view, to a best-in-class safety profile.

• In addition, Charles sees WAKIX as being clinically and commercially de-risked for idiopathic hypersomnia, Harmony’s lead pipeline indication.

• Key upcoming catalysts include quarterly sales in WAKIX as well as upcoming data from early-stage studies.

This marks the first of several Neuro-Innovator company interactions planned this week ahead of Cantor’s Neurology & Psychiatry conference in San Francisco, including two keynote presentations and 11 panels with ~40 companies.

#Cantorconferenceseries #Neurology #Psychiatry #Cantorfitzgerald